Stock Events

Stock Events

Celltrion 

$0
61
+$0+0% Monday 00:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

24
APR
Dividend Payment
Estimated
 

Dividends

0%Dividend Yield
Apr 26
$0.39
Apr 25
$0.39
Apr 24
$0.39
Apr 23
$0.29
Apr 22
$0.63
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8MayExpected
Q4 2023
Q1 2024
0
0.03
0.06
0.08
Expected EPS
0.08298264249
Actual EPS
N/A

Financials

31.32%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
-33.62MRevenue
-10.53MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CONIF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that competes with Celltrion in the development and marketing of biosimilar products and innovative drugs.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, competes in the biopharmaceutical sector, particularly in the areas of immunology and oncology, similar to Celltrion.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology company that competes with Celltrion in the biosimilars market, offering alternatives to biologic drugs in various therapeutic areas.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is involved in the discovery, development, and marketing of pharmaceuticals in areas like oncology, competing directly with Celltrion's product offerings.
Novartis
NVS
Mkt Cap237.61B
Novartis, through its Sandoz division, is a leading company in the biosimilars market, making it a direct competitor to Celltrion in providing biosimilar drugs.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes with Celltrion in the biopharmaceutical field, especially in the development of therapies for autoimmune diseases and biosimilars.
Roche
RHHBY
Mkt Cap258.9B
Roche, with its biotechnology focus, competes in the development of innovative drugs and biosimilars, particularly in oncology and immunology, similar to Celltrion.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is a global biopharmaceutical company that competes with Celltrion in the areas of cancer and immune system-related diseases.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes with Celltrion in the development of innovative therapies, particularly for viral diseases, oncology, and inflammatory diseases.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a global healthcare leader that competes with Celltrion in the biosimilars market and in developing treatments for various diseases, including immunological disorders.

About

Biotechnology
Health Technology
Show more...
CEO
Country
KR
ISIN
KR7068270008

Listings

KQ
KR
068270.KQ

0 Comments

Share your thoughts

FAQ

What is Celltrion stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Celltrion stocks are traded under the ticker CONIF.
What is Celltrion revenue for the last year?▼
Celltrion revenue for the last year amounts to -33.62M USD.
What is Celltrion net income for the last year?▼
CONIF net income for the last year is -10.53M USD.
Does Celltrion pay dividends?▼
Yes, CONIF dividends are paid annual. The last dividend per share was 0.39 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Celltrion located?▼
Celltrion operates in the Professional, Scientific, and Technical Services sector.
When did Celltrion complete a stock split?▼
Celltrion has not had any recent stock splits.